A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

  • End date
    Dec 1, 2025
  • participants needed
  • sponsor
    Nationwide Children's Hospital
Updated on 4 October 2022


This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given.

The study will also evaluate the safety of larotrectinib when given with chemotherapy in your children; as well as the safety larotrectinib when given post-focal radiation therapy.


In this pilot study, we will assess the disease control rate (Continued Complete Response-CCR, Complete Response-CR, Partial Response-PR and Stable Disease-SD) as well as survival rate (overall survival- OS and progression free survival- PFS) in children with newly diagnosed HGG with TRK fusion who receive 2 cycles of larotrectinib monotherapy administered orally, twice daily, at 100 mg/m2 continuously on a 28-day cycle schedule. After 2 monotherapy cycles of larotrectinib, patients with CCR or CR will continue to receive larotrectinib maintenance therapy as monotherapy for a total of 12 cycles. Patients ≤ 48 months with PR or SD after 2 cycles of larotrectinib will go on to receive combination therapy with standard backbone chemotherapy (BABYPOG or HIT-SKK). Patients > 48 months of age (or patients ≥ 36 months of age, or patients with DIPG >18 months of age, at the discretion of the local investigator) will receive focal radiation therapy. A surgical cohort study will be explored whereby patients who have had a tumor biopsy/partial resection at their local institution and are planned to subsequently undergo definitive resection will receive 3-5 days (6-10 doses) of larotrectinib pre-surgery.

The study design of this trial requires 15 patients evaluable for disease control and for safety/ toxicity of larotrectinib as monotherapy. The surgical cohort will enroll up to 4 patients and will count towards the total 15 evaluable patients. A minimum of 6 patients will be evaluable for safety toxicity of larotrectinib in combination with standard-of-care chemotherapy or radiotherapy.

Condition High Grade Glioma
Treatment Larotrectinib
Clinical Study IdentifierNCT04655404
SponsorNationwide Children's Hospital
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Age: Patients ≤ 21 years of age (birth to 21 years of age) at the time of study enrollment will be eligible
Diagnosis: Patients with newly-diagnosed high-grade (HGG), including diffuse intrinsic pontine gliomas (DIPG), whose tumors are documented in a CLIA/CAP certified lab (or clinically equivalent method considered standard in non-US sites) to harbor an NTRK fusion alteration by FISH, PCR, or next generation sequencing are eligible. Patients must have had histologically verified high-grade glioma such as anaplastic astrocytoma, glioblastoma, or H3 K27-mutant diffuse midline glioma verified at a CONNECT site
For sites that do not have CLIA-certified equivalent (certified laboratory) to assess NTRK
fusion, testing will be conducted centrally at NCH. NTRK testing will be performed by NGS
using targeted RNA-sequencing (Archer Solid Tumor analysis) Please submit 10 unstained
sections on charged slides at 10uM thickness, or 10 scrolls cut at 10uM thickness, along
with submission of an H&E slide. Formalin-fixed paraffin embedded (FFPE) tissue block and
FFPE tissue scroll specimens must contain minimum of 25% tumor Snap-frozen tissue specimens
are also acceptable and they must contain a minimum of 10% tumor. Please note that
turn-around time for this test is up to 21 days
Disease Status: Patients with disseminated DIPG or HGG are eligible only if the
patient is to receive chemotherapy only, i.e. no craniospinal RT is intended to be
given. MRI of spine must be performed if disseminated disease is suspected clinically
by the treating physicians. Patients with primary spinal tumors are eligible only if
the patient is to receive either chemotherapy or focal radiation therapy, i.e. no
craniospinal RT is intended to be given. Patients with leptomeningeal disease only
Organ Function Requirements: Adequate Bone Marrow Function Defined as
with no definitive identifiable primary tumor, and documented NTRK fusion, must be
discussed with the Study Chair on a case-by-case basis
Surgical Cohort ONLY: Patients with newly-diagnosed HGG with NTRK fusions who have
undergone prior biopsy and for whom further resection is indicated for a more
definitive surgery at an enrolling site will be eligible to enroll onto the surgical
study. DIPG patients are not eligible for the surgical cohort
Performance Level: Karnofsky ≥ 50% for patients > 16 years of age and Lansky ≥ 50 for
patients ≤ 16 years of age (See Appendix I). Patients who are unable to walk because
of paralysis, but who are up in a wheelchair, will be considered ambulatory for the
purpose of assessing the performance score
Prior Therapy: Patients must not have received any prior anti-cancer chemotherapy
Prior use of corticosteroids are allowed (see below Exclusion Criteria)
Peripheral absolute neutrophil count (ANC) ≥ 1000/mm3 Platelet count ≥ 100,000/mm3
(transfusion independent, defined as not receiving platelet transfusions for at least 7
days prior to enrollment) Hemoglobin >8 g/dL (may receive transfusions)
Adequate Renal Function Defined as: Serum creatinine within normal institutional limits
or Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2
Adequate Liver Function Defined as: Total bilirubin ≤ 2.5 × institutional upper limit of
normal AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal
Adequate Pulmonary Function Defined as: Pulse oximetry > 94% on room air if there is
clinical indication for determination (e.g. dyspnea at rest)
Adequate Neurologic Function Defined as: Patients with seizure disorder may be enrolled
if on anticonvulsants and well controlled. See Section 5.5.2 and Appendix III for EIAED
Informed Consent: All patients and/or their parents or legally authorized representatives
must sign a written informed consent. Assent, when appropriate, will be obtained according
to institutional guidelines

Exclusion Criteria

Patients who have received prior solid organ transplantation are not eligible
Pregnancy or Breast-Feeding: Pregnant or breast-feeding women will not be entered on
this study due to unknown risks of fetal and teratogenic adverse events as seen in
animal/human studies. Pregnancy tests must be obtained in girls who are
post-menarchal. Males or females of reproductive potential may not participate unless
they have agreed to use an effective contraceptive method
Concomitant Medications Investigational Drugs: Patients who have previously received
or are currently receiving another investigational drug are not eligible
Anti-cancer Agents: Patients who have previously received or are currently receiving other
anti-cancer agents, including chemotherapy, immunotherapy, monoclonal antibodies, biologic
or targeted therapy, are not eligible
Infection: Patients must not have any active, uncontrolled systemic bacterial, viral
or fungal infection
Patients must not have malabsorption syndrome or other condition affecting oral
Patients must not be receiving any treatment with a strong cytochrome P450 3A4
(CYP3A4) inhibitor or inducer. (See Appendix III.) Strong inducers or inhibitors of
CYP3A4 should be avoided from 7 days prior to enrollment to the end of the study
Patients who in the opinion of the investigator may not be able to comply with the
safety monitoring requirements of the study are not eligible
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note